KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) Equity Ratio: 2009-2025

Historic Equity Ratio for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Sep 2025 value amounting to 0.05.

  • Alnylam Pharmaceuticals' Equity Ratio rose 526.57% to 0.05 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.05, marking a year-over-year increase of 526.57%. This contributed to the annual value of 0.02 for FY2024, which is 127.46% up from last year.
  • Latest data reveals that Alnylam Pharmaceuticals reported Equity Ratio of 0.05 as of Q3 2025, which was down 12.16% from 0.05 recorded in Q2 2025.
  • Alnylam Pharmaceuticals' 5-year Equity Ratio high stood at 0.28 for Q1 2021, and its period low was -0.12 during Q2 2023.
  • Moreover, its 3-year median value for Equity Ratio was -0.00 (2024), whereas its average is -0.02.
  • As far as peak fluctuations go, Alnylam Pharmaceuticals' Equity Ratio tumbled by 326.94% in 2023, and later spiked by 7,274.95% in 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' Equity Ratio (Quarterly) stood at 0.16 in 2021, then slumped by 127.63% to -0.04 in 2022, then dropped by 29.13% to -0.06 in 2023, then surged by 127.46% to 0.02 in 2024, then skyrocketed by 526.57% to 0.05 in 2025.
  • Its Equity Ratio stands at 0.05 for Q3 2025, versus 0.05 for Q2 2025 and 0.03 for Q1 2025.